Elite in Muscle Invasive Bladder Cancer

Dr. Guru P. Sonpavde

Oncology | Hematology Oncology | Hematology
Florida Hospital Medical Group Inc
2501 N Orange Ave, Suite 689, 
Orlando, FL 
Accepting New Patients
Offers Telehealth
Elite in Muscle Invasive Bladder Cancer
Florida Hospital Medical Group Inc
2501 N Orange Ave, Suite 689, 
Orlando, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Guru Sonpavde is an Oncologist and a Hematologist Oncology provider in Orlando, Florida. Dr. Sonpavde is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Orchiectomy, and Nephrectomy. Dr. Sonpavde is currently accepting new patients.

His clinical research consists of co-authoring 460 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles and participated in 2 clinical trials in the study of Muscle Invasive Bladder Cancer.

Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in TX
Hospital Affiliations
Adventhealth Orlando
Adventhealth Waterman
Languages Spoken
English
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

FLORIDA HOSPITAL MEDICAL GROUP INC
2501 N Orange Ave, Suite 689, Orlando, FL 32804

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Combinations of Sacituzumab Govitecan Plus Enfortumab Vedotin and Pembrolizumab for Metastatic Urothelial Carcinoma: the Double Antibody Drug Conjugate (DAD) and Double Antibody Drug Conjugate With Immunotherapy (DAD-IO) Phase I/II Trial
Combinations of Sacituzumab Govitecan Plus Enfortumab Vedotin and Pembrolizumab for Metastatic Urothelial Carcinoma: the Double Antibody Drug Conjugate (DAD) and Double Antibody Drug Conjugate With Immunotherapy (DAD-IO) Phase I/II Trial
Enrollment Status: Enrolling_by_invitation
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV)
Study Phase: Phase 1/Phase 2
Phase I/II Study of Ipilimumab Plus Nivolumab (IPI-NIVO) Combined With Sacituzumab Govitecan (SG)as First-line Treatment for Cisplatin-ineligible Metastatic Urothelial Carcinoma
Phase I/II Study of Ipilimumab Plus Nivolumab (IPI-NIVO) Combined With Sacituzumab Govitecan (SG)as First-line Treatment for Cisplatin-ineligible Metastatic Urothelial Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab, Sacituzumab govitecan
Study Phase: Phase 1/Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients With High Grade Upper Tract Urothelial Carcinoma
A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients With High Grade Upper Tract Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: July 10, 2023
Intervention Type: Procedure, Drug
Study Drugs: Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine, Carboplatin, Pegfilgrastim
Study Phase: Phase 2
Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer
Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug, Procedure, Other
Study Drugs: Enzalutamide, Bicalutamide, Leuprolide acetate, Goserelin acetate
Study Phase: Phase 2
A Feasibility Study of Durvalumab (MEDI4736) Alone or in Combination With Oleclumab (MEDI9447) as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
A Feasibility Study of Durvalumab (MEDI4736) Alone or in Combination With Oleclumab (MEDI9447) as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
Enrollment Status: Completed
Publish Date: September 13, 2022
Intervention Type: Drug
Study Drugs: Durvalumab, Oleclumab
Study Phase: Phase 1
Biomarker-directed Neoadjuvant Therapy for Cisplatin-ineligible or Cisplatin-refusing Muscle-invasive Bladder Cancer: Phase I Bladder Cancer Signal Seeking Trial
Biomarker-directed Neoadjuvant Therapy for Cisplatin-ineligible or Cisplatin-refusing Muscle-invasive Bladder Cancer: Phase I Bladder Cancer Signal Seeking Trial
Enrollment Status: Withdrawn
Publish Date: August 10, 2022
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 1
Phase II Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Following Previous Chemotherapy
Phase II Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Following Previous Chemotherapy
Enrollment Status: Terminated
Publish Date: June 21, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Enrollment Status: Completed
Publish Date: April 27, 2022
Intervention Type: Biological
Study Drugs: CV-301, Atezolizumab
Study Phase: Phase 2
BLASST-1 (Bladder Cancer Signal Seeking Trial): Phase II Trial of Neoadjuvant Nivolumab With Cisplatin and Gemcitabine in Muscle-Invasive Bladder Cancer (MIBC) Patients Undergoing Radical Cystectomy
BLASST-1 (Bladder Cancer Signal Seeking Trial): Phase II Trial of Neoadjuvant Nivolumab With Cisplatin and Gemcitabine in Muscle-Invasive Bladder Cancer (MIBC) Patients Undergoing Radical Cystectomy
Enrollment Status: Completed
Publish Date: December 16, 2021
Intervention Type: Drug
Study Drugs: Nivolumab, Cisplatin, Gemcitabine
Study Phase: Phase 2
Phase I Trial of Prednisone, Abiraterone, Cabazitaxel and Enzalutamide (PACE) for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase I Trial of Prednisone, Abiraterone, Cabazitaxel and Enzalutamide (PACE) for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Withdrawn
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Multicenter, Non-Randomized, Phase II Study of Regorafenib for Advanced Urothelial Cancer Following Prior Chemotherapy
A Multicenter, Non-Randomized, Phase II Study of Regorafenib for Advanced Urothelial Cancer Following Prior Chemotherapy
Enrollment Status: Completed
Publish Date: August 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma Following Systemic Therapy
A Phase 2 Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma Following Systemic Therapy
Enrollment Status: Terminated
Publish Date: April 14, 2020
Intervention Type: Drug
Study Phase: Phase 2
Phase 1b/2 Study of LY3200882 and Pembrolizumab in Patients With Advanced Cancer
Phase 1b/2 Study of LY3200882 and Pembrolizumab in Patients With Advanced Cancer
Enrollment Status: Withdrawn
Publish Date: February 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Chemotherapy and Androgen Pathway Inhibitors
A Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Chemotherapy and Androgen Pathway Inhibitors
Enrollment Status: Completed
Publish Date: December 19, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 26, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 18 Less Clinical Trials

460 Total Publications

End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 11, 2025
Similar Doctors
Distinguished in Muscle Invasive Bladder Cancer
Dr. Carlos A. Alemany
Hematology Oncology | Oncology
Distinguished in Muscle Invasive Bladder Cancer
Dr. Carlos A. Alemany
Hematology Oncology | Oncology

Florida Hospital Medical Group Inc

2600 Westhall Ln, 
Maitland, FL 
 (4.5 miles away)
407-200-2700
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Carlos Alemany is a Hematologist Oncology specialist and an Oncologist in Maitland, Florida. Dr. Alemany is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and WT1-Related Wilms Tumor Syndromes. Dr. Alemany is currently accepting new patients.

Advanced in Muscle Invasive Bladder Cancer
Dr. Amit C. Barochia
Oncology | Hematology | Hematology Oncology
Advanced in Muscle Invasive Bladder Cancer
Dr. Amit C. Barochia
Oncology | Hematology | Hematology Oncology

Health First Medical Group LLC

490 N Washington Ave, 
Titusville, FL 
 (33.9 miles away)
321-268-4000
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Amit Barochia is an Oncologist and a Hematologist in Titusville, Florida. Dr. Barochia is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Lung Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Familial Colorectal Cancer. Dr. Barochia is currently accepting new patients.

Advanced in Muscle Invasive Bladder Cancer
Dr. Ahmed Al
Hematology | Oncology
Advanced in Muscle Invasive Bladder Cancer
Dr. Ahmed Al
Hematology | Oncology

Florida Cancer Specialists And Research Institute, LLC

1340 N Hancock Rd, 
Clermont, FL 
 (23.3 miles away)
352-394-1150
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ahmed Al is a Hematologist and an Oncologist in Clermont, Florida. Dr. Al is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lung Cancer, and Pleuropulmonary Blastoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sonpavde's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile